Novartis Extends Alnylam RNAi Rx Partnership for Fifth Year

The deal was first announced in Sept. 2005, and called for Alnylam to optimize certain of Novartis' lead RNAi drug candidates, which Novartis would develop and commercialize.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.